Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 6
2008 13
2009 4
2010 5
2011 5
2012 7
2013 2
2014 6
2015 9
2016 8
2017 13
2018 8
2019 9
2020 7
2021 12
2022 15
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
Koizumi H, Gomi F, Tsujikawa A, Honda S, Mori R, Ochi H, Iwasaki K, Okada AA; TENAYA and LUCERNE Investigators. Koizumi H, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Mar 14. doi: 10.1007/s00417-024-06377-1. Online ahead of print. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38483611
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Central serous chorioretinopathy: An evidence-based treatment guideline.
Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, Larsen M, Querques G, Downes SM, Yzer S, Breazzano MP, Subhi Y, Tadayoni R, Priglinger SG, Pauleikhoff LJB, Lange CAK, Loewenstein A, Diederen RMH, Schlingemann RO, Hoyng CB, Chhablani JK, Holz FG, Sivaprasad S, Lotery AJ, Yannuzzi LA, Freund KB, Boon CJF. Feenstra HMA, et al. Among authors: koizumi h. Prog Retin Eye Res. 2024 Jan 31:101236. doi: 10.1016/j.preteyeres.2024.101236. Online ahead of print. Prog Retin Eye Res. 2024. PMID: 38301969 Free article. Review.
Scleral Thickness in Simple Versus Complex Central Serous Chorioretinopathy.
Imanaga N, Terao N, Wakugawa S, Miyara Y, Sawaguchi S, Oshiro A, Yamauchi Y, Koizumi H. Imanaga N, et al. Among authors: koizumi h. Am J Ophthalmol. 2024 May;261:103-111. doi: 10.1016/j.ajo.2024.01.025. Epub 2024 Jan 26. Am J Ophthalmol. 2024. PMID: 38281567 Free article.
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, Matsumoto H, Mukai R, Nagai Y, Ohnaka M, Kusuhara S, Miki A, Okada AA, Nakayama M, Nishiguchi KM, Takeuchi J, Mori R, Tanaka K, Honda S, Kohno T, Koizumi H, Miyara Y, Inoue Y, Takana H, Iida T, Maruko I, Hayashi A, Ueda-Consolvo T, Yanagi Y. Inoda S, et al. Among authors: koizumi h. Retina. 2024 Apr 1;44(4):714-722. doi: 10.1097/IAE.0000000000004009. Retina. 2024. PMID: 38016089
Vogt-Koyanagi-Harada disease in a patient with extreme anisometropia.
Maehira M, Oshiro A, Imanaga N, Yamauchi Y, Koizumi H. Maehira M, et al. Among authors: koizumi h. Am J Ophthalmol Case Rep. 2023 Sep 21;32:101929. doi: 10.1016/j.ajoc.2023.101929. eCollection 2023 Dec. Am J Ophthalmol Case Rep. 2023. PMID: 37771387 Free PMC article.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Kataoka K, et al. Among authors: koizumi h. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37668741
Clinical Characteristics and Progression of Geographic Atrophy in a Japanese Population.
Sato Y, Ueda-Arakawa N, Takahashi A, Miyara Y, Hara C, Kitajima Y, Maruko R, Kawai M, Takahashi H, Koizumi H, Kawasaki R, Maruyama-Inoue M, Yanagi Y, Iida T, Takahashi K, Sakamoto T, Tsujikawa A. Sato Y, et al. Among authors: koizumi h. Ophthalmol Retina. 2023 Oct;7(10):901-909. doi: 10.1016/j.oret.2023.06.004. Epub 2023 Jun 9. Ophthalmol Retina. 2023. PMID: 37302656 Free article.
Effects of internal limiting membrane peeling on anatomical and functional outcomes in macula-off rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy: Japan-Retinal Detachment Registry.
Obata S, Sawada O, Kakinoki M, Matsumoto R, Saishin Y, Ohji M; Japan-Retinal Detachment Registry Group. Obata S, et al. Jpn J Ophthalmol. 2023 Jul;67(4):417-423. doi: 10.1007/s10384-023-01000-y. Epub 2023 Jun 8. Jpn J Ophthalmol. 2023. PMID: 37289298
130 results